Setmelanotide (Imcivree): MC4R Agonist Evidence in 2026

A precision-medicine peptide, not a general obesity drug

Setmelanotide is the only melanocortin-4 receptor (MC4R) agonist with regulatory approval in obesity, and the entire commercial story is built on patients whose MC4R signaling is broken upstream by a specific genetic or anatomic defect. The drug works powerfully when the defect is the right kind, and barely at all when it is not. That contrast is the whole article. If you treat setmelanotide like a GLP-1 alternative for general weight loss, you will draw the wrong conclusion from the trial data.

The four FDA-approved indications, in order of approval, are biallelic POMC, PCSK1, or LEPR deficiency (2020), Bardet-Biedl syndrome (2022), the same indications in children aged 2 to 5 years (2024), and acquired hypothalamic obesity (March 19, 2026). The 2026 approval was supported by the TRANSCEND Phase 3 trial in 120 patients with hypothalamic injury from surgery, chemotherapy, or radiation for non-malignant suprasellar tumors. In parallel, the EMANATE Phase 3 program in heterozygous carriers of POMC, PCSK1, LEPR, SRC1, and SH2B1 variants missed every primary endpoint. Both readouts landed in the same window. Together they map exactly where the molecule earns its keep.

Bottom line: Setmelanotide is a daily subcutaneous MC4R agonist that produces 15 to 25 percent BMI reductions in patients with biallelic monogenic obesity, Bardet-Biedl syndrome, or acquired hypothalamic obesity, and near-zero benefit in patients with heterozygous variants of the same pathway genes. The mechanism is the same in both groups. The biology of the upstream defect is what changes the answer.

What setmelanotide is at the molecular level

Setmelanotide is a synthetic cyclic octapeptide and selective MC4R agonist. The structure is based on the endogenous ligand alpha-melanocyte-stimulating hormone (alpha-MSH), with substitutions and a lactam ring that lock it into a high-affinity conformation at MC4R while keeping reasonable potency at MC1R and MC3R. The injectable formulation is delivered once daily subcutaneously and titrated up to a maintenance dose of 3 mg.

The melanocortin pathway runs as follows. Leptin signals through LEPR on hypothalamic neurons. Those neurons release alpha-MSH, which acts on MC4R-expressing neurons in the paraventricular nucleus. MC4R activation suppresses appetite and increases energy expenditure. If any step upstream is broken (LEPR mutation, POMC deficiency, PCSK1 processing defect, BBS ciliary dysfunction in MC4R neurons, or anatomic destruction of the hypothalamus), the downstream MC4R receptor is intact but receiving no signal. Setmelanotide bypasses the missing signal by binding MC4R directly.

That is also why heterozygous variants of pathway genes (one bad copy, one working copy) do not produce a strong response. The pathway is dimmed, not silenced, and a downstream agonist cannot pull the system into a meaningfully different state. EMANATE was designed to test that hypothesis. The result is consistent with the model.

The MC1R cross-activation is the reason setmelanotide users develop tan and darker moles. It is also the same biology that makes melanotan II a research peptide for tanning and PT-141 work as a libido peptide through central MC3R and MC4R activation. Setmelanotide is the cleanest MC4R-selective agonist of the three.

The four approved indications at a glance

All four indications share a common feature: the patient cannot generate or transmit a functional MC4R signal because of a defect upstream of the receptor. None of the indications cover heterozygous variant carriers, general adult obesity, or hypothalamic obesity from causes other than non-malignant tumor-related injury.

TRANSCEND: the 2026 hypothalamic obesity approval

Acquired hypothalamic obesity is the brain-tumor side of the setmelanotide story. After surgery, chemotherapy, or radiation for craniopharyngiomas and similar non-malignant suprasellar tumors, patients can develop progressive, treatment-resistant obesity driven by direct damage to the hypothalamic satiety circuits. Bariatric surgery and conventional weight-loss medications have historically underperformed in this population because the lesion is anatomic, not behavioral. The US prevalence is estimated at roughly 10,000 patients.

TRANSCEND (NCT05774756) was the global, randomized, double-blind, placebo-controlled Phase 3 trial that supported the March 19, 2026 FDA label expansion. The trial enrolled 120 patients aged 4 and older with acquired hypothalamic obesity, randomized 2:1 to setmelanotide or placebo daily for 52 weeks.

Reported topline results from the Rhythm Pharmaceuticals 2025 readout and the 2026 FDA approval announcement:

• Mean change in BMI at 52 weeks: -16.5% on setmelanotide versus +3.3% on placebo
• Placebo-adjusted BMI difference: -19.8% (P less than .0001)
• Hunger improvement in patients aged 12 and older: 2.5-point weekly reduction in "most hunger" score on setmelanotide versus 1.3 points on placebo (P = .0015)
• Safety profile aligned with prior approvals: nausea, vomiting, hyperpigmentation, no new signals

The Phase 2 lead-in for this indication was published as Roth et al., Lancet Diab Endo 2024 (PMID 38697184). Eighteen patients aged 6 to 40 received setmelanotide titrated to 3 mg daily for 16 weeks. Sixteen of 18 (89%) met the primary endpoint of at least 5% BMI reduction from baseline. The mean BMI reduction across all patients was 15% (SD 10), and a sub-cohort followed into the long-term extension reached roughly 26% mean BMI reduction at one year. Both the Phase 2 and Phase 3 readouts pointed the same direction and supported the label expansion.

Note: The Phase 3 TRANSCEND topline numbers above are from Rhythm Pharmaceuticals investor materials and the FDA approval announcement. The full peer-reviewed Phase 3 publication had not appeared on PubMed at the time of writing. The Phase 2 data (Roth 2024) is fully peer-reviewed and is the strongest published evidence to date in this indication.

Clement 2020: the original POMC and LEPR approvals

The 2020 FDA approval of setmelanotide rested on two single-arm, open-label, multicenter Phase 3 trials reported in Clement et al., Lancet Diab Endo 2020 (PMID 33137293). The trials enrolled patients aged 6 and older with biallelic POMC, PCSK1, or LEPR deficiency in ten hospitals across Canada, the US, Belgium, France, Germany, the Netherlands, and the UK.

Trial design and results:

• 12 weeks of open-label setmelanotide, then patients meeting a weight-loss responder threshold entered an 8-week placebo-controlled withdrawal sequence, then 32 more weeks of open-label treatment
• Primary endpoint: proportion of patients achieving at least 10% body weight reduction at 1 year
• POMC deficiency cohort: 8 of 10 (80%) achieved at least 10% weight loss
• LEPR deficiency cohort: 5 of 11 (46%) achieved at least 10% weight loss
• Mean weight change at 1 year: -25.6% in POMC patients, -12.5% in LEPR patients
• Hunger scores improved substantially in both cohorts during the active phase and worsened during placebo withdrawal

The two-cohort design with a placebo-controlled withdrawal phase is unusual but appropriate for ultra-rare diseases. The withdrawal data showed weight regain and hunger return in patients pulled off setmelanotide, which strengthens the case that the response is drug-driven rather than secular or behavioral.

Haqq 2022: Bardet-Biedl syndrome (and the negative Alstrom signal)

Bardet-Biedl syndrome (BBS) is a ciliopathy that disrupts MC4R neuron function through impaired primary cilium signaling in the hypothalamus. Alstrom syndrome is a related ciliopathy with overlapping but distinct genetics. Rhythm tested setmelanotide in both populations in a single Phase 3 trial. The trial separated the two indications in the analysis, and that separation mattered.

Haqq et al., Lancet Diab Endo 2022 (PMID 36356613) was a multicenter, randomized, double-blind, placebo-controlled Phase 3 with an open-label extension. The trial enrolled 32 BBS patients and 10 Alstrom patients aged 6 and older across North America and Europe, all with obesity defined as weight greater than the 97th percentile (for ages 6 to 15) or BMI of at least 30 (for ages 16 and older).

Key BBS results at 52 weeks of open-label treatment after the 14-week placebo-controlled phase:

• Mean BMI change: -7.9% (placebo-adjusted, the prespecified primary analysis was positive)
• Proportion of BBS patients aged 12 and older losing at least 10% body weight: 32%
• Significant reductions in hunger scores
• Quality of life improvements reported in the parallel paper Forsythe et al. Orphanet J Rare Dis 2023 (PMID 36647077)

The Alstrom cohort did not show a significant BMI reduction. The most plausible reason is that Alstrom syndrome causes a broader spectrum of metabolic and ciliary dysfunction, with insulin resistance and progressive multi-organ involvement that may overwhelm a peptide acting through one node of the hypothalamic circuit. The FDA approved setmelanotide for BBS but not for Alstrom.

This is the cleanest published example of an indication-by-indication readout shaping the regulatory path. The trial enrolled both populations, the drug worked in one and not the other, and the label tracked the data exactly.

VENTURE: extending the label to ages 2 to 5

The VENTURE trial (Argente et al., Lancet Diab Endo 2024, PMID 39549719) extended setmelanotide use into children aged 2 to 5 with MC4R pathway-associated obesity. VENTURE was a 1-year, open-label, multicenter, Phase 3 trial in 12 children with either POMC, PCSK1, LEPR biallelic variants or BBS.

At 1 year:

• Mean BMI Z-score change: -3.04
• Mean percent change in BMI: -27.1%
• 10 of 12 patients met the primary endpoint
• Hyperphagia improved in line with prior cohorts

VENTURE supported the December 2024 label expansion to ages 2 and older. That filled the only meaningful pediatric gap in setmelanotide's approval set.

EMANATE: where the drug stopped working

EMANATE (NCT05093634) was the four-cohort Phase 3 program in heterozygous variant carriers of POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1. The biological premise was that even a partial loss of upstream signaling tone might be partially correctable by a downstream MC4R agonist. The clinical question was whether a label expansion from ~10,000 biallelic patients to roughly 50,000 to 100,000 heterozygous carriers in the US was achievable on the same molecule.

The answer, reported in 2026 Rhythm Pharmaceuticals topline, was no.

The numerical effect sizes in three of four cohorts were not zero, and the company has flagged POMC/PCSK1 and SRC1 (NCOA1) as continued development candidates with its next-generation MC4R agonists bivamelagon and RM-718. But on the registration endpoint, EMANATE did not deliver. The genetics matter. A 4% placebo-adjusted BMI reduction at 52 weeks is on par with what a year of careful lifestyle change can produce, and it is roughly an order of magnitude below the response seen in biallelic, BBS, and acquired hypothalamic obesity.

This is the cleanest negative result in the MC4R agonist field. It says, with Phase 3 statistical weight, that being a carrier of one pathway variant does not produce a treatment-responsive phenotype. That is genuinely useful information for clinical genetics and for the broader question of whether common MC4R-pathway polymorphisms in the general obesity population could ever be targeted with this kind of drug.

Dosing, half-life, and what daily injection actually looks like

Setmelanotide is supplied as a sterile aqueous solution in 10 mg/mL multi-dose vials for daily subcutaneous administration. The label dose is titrated up from 1 mg to a maintenance dose of 2 mg or 3 mg daily depending on indication, age, and tolerability. Children titrate more slowly and to lower maintenance doses.

Pharmacokinetic features from the label and prior studies:

• Route: subcutaneous, daily
• Cmax: roughly 6 to 8 hours after injection
• Half-life: approximately 11 hours, supporting daily but not weekly dosing
• Steady state: reached within about 2 days
• Metabolism: peptide hydrolysis, no significant CYP involvement, so few drug interactions

The daily injection burden is the main practical liability versus modern weekly GLP-1 agonists. For a rare-disease patient with no realistic alternative, daily injection is acceptable. For a general-obesity patient, it is not, and that fact alone would limit the molecule to its current indications even if EMANATE had been positive.

Side effects: the MC1R hyperpigmentation problem

The setmelanotide adverse event profile from the Roth 2024 Phase 2 hypothalamic obesity trial and the BBS Phase 3 looks roughly like this:

• Nausea: 30 to 60% across trials
• Vomiting: 20 to 35%
• Injection site reactions: common, usually mild
• Skin hyperpigmentation: 30 to 50%, mostly diffuse tanning
• Darkening of pre-existing nevi: reported, requires dermatologic monitoring
• Diarrhea, headache, fatigue: less common
• Serious adverse events: rare in published trials, no consistent signal

The hyperpigmentation is mechanism-based. MC1R activation in skin melanocytes increases eumelanin production, which is the same effect that recreational melanotan II users seek. Setmelanotide is more MC4R-selective than melanotan II, but at therapeutic doses for 52 weeks the MC1R activity is enough to produce visible skin and mole darkening in roughly a third to half of patients. The label requires baseline and ongoing skin examinations, including full-body photography, because of the possibility that pre-existing melanocytic lesions could be obscured or transformed by chronic MC1R activation.

A related consideration: setmelanotide can cause spontaneous penile erections through central MC3R and MC4R activation, the same pathway that powers PT-141. The effect is dose-dependent, more pronounced early in titration, and listed on the label.

How setmelanotide fits next to GLP-1s

Setmelanotide and GLP-1 receptor agonists are not competing therapies in any meaningful sense. They target different populations, work through different circuits, and produce different effect sizes.

For the small populations setmelanotide is approved in, no GLP-1 is a substitute. For everyone else, the GLP-1 / GIP / GCG class is the standard of care. The relevant background reading on the GLP-1 side is in our semaglutide vs tirzepatide 2026 comparison, the retatrutide triple agonist guide, and the Maridebart cafraglutide Phase 2 readout. For oral GLP-1 specifically, the orforglipron Phase 3 evidence writeup tracks where Lilly's oral candidate sits.

What this means for the broader peptide research community

Most readers of this site are not patients with biallelic POMC deficiency or post-craniopharyngioma hypothalamic obesity. The interesting question for the research community is what setmelanotide tells us about MC4R as a drug target more generally.

Three takeaways:

1. MC4R agonism produces real, large weight loss when the upstream defect creates a need for it. This is rare-disease pharmacology working as designed: replace the missing signal, get a large response. The TRANSCEND, BBS Phase 3, and Clement POMC/LEPR readouts agree on this.
2. MC4R agonism does very little in heterozygous variant carriers. EMANATE is a clean negative. The implication is that targeting common MC4R-pathway polymorphisms in general obesity is harder than it looked five years ago, and that the next generation of MC4R agonists may need to be paired with another mechanism (likely a GLP-1) to produce general-obesity-sized effect sizes.
3. Daily subcutaneous dosing constrains the addressable market. Even if a hypothetical setmelanotide-class drug worked in general obesity, weekly competitors with comparable efficacy would dominate adoption. The next-generation MC4R agonists Rhythm has in development (bivamelagon and RM-718) are testing whether the pharmacology can be moved to less burdensome dosing.

For research-use peptides on the melanocortin axis, the practical action is downstream. PT-141 (bremelanotide) is the central MC4R-targeting peptide most relevant to libido research. Melanotan II is the broader-spectrum melanocortin agonist used in tanning research. Setmelanotide itself is a prescription drug with a six-figure annual list price and is not available through research peptide vendors. Anything sold under that name from a research peptide source should be treated as misbranded.

Practical considerations for clinicians and patients

Setmelanotide is approved, expensive, and narrow. The path from a hypothalamic obesity diagnosis to a prescription typically runs through a tertiary-care endocrinology or obesity medicine center, with prior-authorization documentation and (often) participation in the Rhythm support program. Common access bottlenecks:

• Genetic testing requirement for the POMC, PCSK1, LEPR, and BBS indications
• Confirmation of acquired hypothalamic injury from a qualifying non-malignant tumor and treatment history for the 2026 indication
• Prior authorization with payer-specific BMI, age, and prior-therapy criteria
• Dermatologic baseline assessment before initiation
• Patient or caregiver capacity to administer daily subcutaneous injections

For research-use peptide users who are reading this article to compare setmelanotide to peptides they can actually access, the honest answer is that setmelanotide is not a substitute for, or competitor with, BPC-157, TB-500, GHK-Cu, tirzepatide, semaglutide, retatrutide, or any other compound in the typical research catalog. It targets a different problem in a different population through a different receptor.

For the closest research-peptide adjacencies on the melanocortin axis, Ascension Peptides carries PT-141 for libido research with 50% off using code ENHANCED, and our PT-141 bremelanotide guide covers the underlying MC4R biology that setmelanotide and PT-141 share.

Where the field goes from here

Three near-term questions matter:

• Will the next-generation MC4R agonists (bivamelagon, RM-718) recover anything in heterozygous variant populations? EMANATE's 4% placebo-adjusted effects in some cohorts are too small to be a registration endpoint but big enough to motivate continued development. A more potent or biased MC4R agonist might or might not move that needle.
• Will setmelanotide combine with GLP-1 agonists in monogenic obesity? Most rare-disease patients on setmelanotide do not have access to a GLP-1 trial. Pharmacology suggests additive effect sizes if the MC4R pathway and the incretin pathway both contribute meaningfully. No combination trial has been reported.
• Will the TRANSCEND data hold up in real-world hypothalamic obesity? TRANSCEND enrolled patients with non-malignant tumor-related hypothalamic injury. Real-world hypothalamic obesity includes a broader population of trauma, infection, and idiopathic cases. The label is narrower than the underlying biology suggests.

For now, setmelanotide's story is finished where it is well-defined and unresolved where the next move depends on whether MC4R agonism can be made more useful outside its current population.

Further reading

• PT-141 (bremelanotide) libido peptide guide
• Tirzepatide vs semaglutide 2026 head to head
• Retatrutide explained: triple agonist
• Maridebart cafraglutide (MariTide) Phase 2 evidence
• Orforglipron Phase 3 evidence
• GLP-1 muscle loss research
• PT-141 compound page
• Melanotan II compound page
• Reconstitution calculator

References

1. Clement K, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960-970. PMID 33137293
2. Haqq AM, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859-868. PMID 36356613
3. Roth CL, et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024;12(6):380-389. PMID 38697184
4. Argente J, et al. Setmelanotide in patients aged 2 to 5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol. 2024;13(1):29-40. PMID 39549719
5. Forsythe E, et al. Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet-Biedl syndrome: phase 3 trial results. Orphanet J Rare Dis. 2023;18(1):12. PMID 36647077

---

This article is for educational and research purposes only. None of the content above constitutes medical advice. Setmelanotide (Imcivree) is a prescription medication available only through licensed clinical channels for its approved indications. Material sold under the setmelanotide name through research peptide vendors is not the same product. Decisions about rare-disease obesity treatment belong with the patient, family, and treating endocrinologist or obesity medicine specialist.